Please login to the form below

Not currently logged in
Email:
Password:

immunodeficiency

This page shows the latest immunodeficiency news and features for those working in and with pharma, biotech and healthcare.

GSK hands rare disease assets over to Orchard

GSK hands rare disease assets over to Orchard

severe combined immunodeficiency (ADA-SCID) or ‘bubble boy’disease - might do better outside the company.

Latest news

  • NICE backs GSK’s ‘bubble baby’ gene therapy NICE backs GSK’s ‘bubble baby’ gene therapy

    NICE backs GSK’ s ‘ bubble baby’ gene therapy. Strimvelis will treat children under the NHS for immunodeficiency. ... Strimvelis was approved by the European Medicines Agency (EMA) last year to treat severe combined immunodeficiency due to

  • Janssen wins European approval for Symtuza Janssen wins European approval for Symtuza

    The European Commission (EC) has approved Janssen’s Symtuza (darunavir-STR) to treat adults with human immunodeficiency virus type 1 (HIV-1).

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    GlaxoSmithKline (GSK) got the green light from the CHMP for Strimvelis (GSK2696273) as a treatment for rare disease ADA-SCID - severe combined immunodeficiency due to adenosine deaminase deficiency - which is also

  • Mixed news for gene therapies at ASH conference Mixed news for gene therapies at ASH conference

    GlaxoSmithKline (GSK) reported positive results in a trial of a gene therapy for Wiskott– Aldrich syndrome (WAS), a rare genetic disorder that results in immunodeficiency and complication such as cancer. ... The successful trial comes after GSK became

  • Shire makes shock $30bn bid for Baxalta Shire makes shock $30bn bid for Baxalta

    The new crop of products that Baxalta is banking on - and which Shire wants to gain access - include primary immunodeficiency therapy HyQvia, launched in the US last October, and long-acting

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    years. Initial disease targets include cancer, neuromuscular disease, haemophilia, immunodeficiencies and blindness.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics